Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
192
resultados
Última actualización
15/06/2025 [06:53:00]
Resumen de: FR3156311A1
La présente invention concerne une nanoparticule radioactive de type cœur/enveloppe comprenant : - un cœur à base de silice poreuse comprenant un ou plusieurs radionucléide(s) émetteur(s) α et un ou plusieurs radionucléide(s) émetteur(s) β, et - une enveloppe métallique. La présente invention concerne également l’utilisation de cette nanoparticule radioactive comme médicament, notamment dans la prévention et/ou le traitement du cancer, et/ou comme agent d’imagerie.
Resumen de: AU2023369585A1
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
Resumen de: CN120131587A
本发明涉及阿霉素脂质体纳米药物的制备方法与应用领域，具体涉及一种地高辛为第五组分的可离子化阿霉素脂质体纳米药物的制备方法及其应用，利用可离子化脂质递送载体在肿瘤组织的酸性微环境作用下的质子化作用(具有叔胺结构的哌嗪在酸性条件下质子化形成阳离子)，与质子化的DOX发生排斥，实现快速、高效释放DOX，降低DOX@D‑LNP的毒副作用；利用具有心血管保护作用的药物DIG降低DOX介导的心脏毒性；同时利用DIG的抗肿瘤作用，提高DOX@D‑LNP的抗肿瘤效果。
Resumen de: CN120131974A
本发明涉及一种基因编辑递送载体、递送系统及其制备方法和应用。该载体为利用苯硼酸对线性聚乙烯亚胺改性制得获得的细胞核靶向高分子载体。利用该载体制备的纳米颗粒和纳米递送系统，无需进行额外的传统核定位序列(NLS)肽修饰，即可具有超高的细胞核靶向能力，能够在活细胞及体内水平进行高效的基因编辑，并在细胞核区域对目的基因进行实时成像，显著提高了活细胞和体内基因编辑的效率和核酸检测的准确性。同时具有易于制备、基因编辑效率高、检测灵敏度高等优点。
Resumen de: CN120132005A
本发明提供了一种具有抗菌和成像功能的钛酸钡/铋@聚吡咯纳米材料及其制备方法和应用。包括：S1.用水热法制备钛酸钡；S2.在钛酸钡纳米颗粒表面负载铋单质，构建钛酸钡/铋异质结；S3.在冰水浴下，将钛酸钡/铋异质结与预氧化的吡咯单体复合，制成钛酸钡/铋@聚吡咯纳米材料。本发明制备的钛酸钡/铋@聚吡咯纳米材料具有良好的生物相容性，优异的抗菌和成像性能，可用于创面或骨缺损修复等领域，可实现非侵入性、高效性和可控性抗菌，并可用于实时监测。
Resumen de: CN120131653A
本发明公开了谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合、纳米颗粒递送系统及其应用，属于医药领域。本发明证明SLC7A11在肺腺癌中显著过表达，并与不良临床预后相关；通过实验发现谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合在中高SLC7A11表达细胞中表现出增强肺腺癌治疗效果，同时在低表达细胞中也能达到与SLC7A11过表达条件下葡萄糖剥夺相当的效果。为了优化递送方式并最小化全身毒性，本发明还制备了一种双细胞膜包被双药的纳米颗粒递送系统，该系统表现出增强肿瘤靶向和药物可控释放能力，有效解决了肿瘤中SLC7A11表达差异(异质性)问题，并在临床前模型中展示出显著的抗肿瘤效果，为肺腺癌的治疗提供了一种有前景的治疗方法。
Resumen de: CN120131584A
本发明公开了一种纳米药物及其制备方法与应用，涉及生物医药技术领域。本发明的纳米药物包括纳米颗粒和包裹于纳米颗粒中的活性药物；所述纳米颗粒包括载体和修饰于载体表面的靶向肽；所述活性药物为疏水性BCL‑2蛋白抑制剂；所述载体包括甲氧基聚乙二醇聚乳酸‑羟基乙酸共聚物；所述靶向肽包括cRGD肽。本发明的纳米药物基于活化血小板在肿瘤转移中的重要作用，采用cRGD肽修饰的载体靶向递送ABT‑737，特异性诱导活化血小板的凋亡，降低对静息血小板及正常组织的影响，药物的毒副作用降低，显著抑制黑色素瘤肺转移，增强PD‑1抗体的抗转移疗效；本发明的纳米药物基于血小板在多种肿瘤转移中的支持作用，可进一步拓展至黑色素瘤外的其他癌症类型晚期转移的治疗。
Resumen de: CN120131586A
本发明公开了一种光磁可视化生物杂化纳米体系及其制备方法和应用，所述光磁可视化生物杂化纳米体系包括血小板膜以及包裹在所述血小板膜内的负载氯沙坦的单宁酸锰络合物；本发明光磁可视化生物杂化纳米体系能够促进药物和免疫细胞的深层渗透性，并利用血小板膜的生物趋向性实现肿瘤靶向治疗，此外，还能够通过荧光成像和磁成像双重成像模式为精准靶向治疗提供可视化跟踪。
Resumen de: CN120131919A
本发明涉及医用制剂技术领域，具体公开了一种硒基抗绝经后骨质疏松药物及其制备方法和应用，包括：主活性成分，为纳米硒‑植物雌激素复合物，由硒代蛋氨酸与大豆异黄酮通过共价偶联形成，其粒径为50‑200nm，硒元素质量占比为复合物的5％‑30％；辅助活性成分，为胶原肽‑钙螯合物，由海洋胶原肽与柠檬酸钙通过螯合反应制备，钙元素与胶原肽的质量比为1:3‑1:5；靶向递送载体，为叶酸修饰的壳聚糖纳米粒，负载所述主活性成分与辅助活性成分；辅料，包括崩解剂、润滑剂及pH敏感型肠溶包衣材料；本发明通过主活性成分纳米硒‑植物雌激素复合物与辅助活性成分胶原肽‑钙螯合物的协同作用，能够同时促进骨形成与抑制骨吸收，实现了双功能治疗。
Resumen de: CN120131947A
本发明公开了一种多酚包覆的金属氧化物纳米颗粒及其制备方法与应用，所述的纳米颗粒包括掺杂或不掺杂其他金属的金属氧化物内核和多酚类化合物壳层，本发明所述的材料具有作为多种医学影像造影剂的潜力，同时兼具清除活性氧以减少氧化应激的能力，作为诊疗一体化体系的应用潜力较大，此外，本发明的纳米颗粒的制备方法简单，生产成本低等。
Resumen de: CN120131585A
本发明涉及医药技术领域，尤其涉及一种新型纳米颗粒递药系统的制备方法及应用；包括以下步骤：A、将活化后的牛血清白蛋白加入到孔板中，再加入2‑吗啉乙磺酸缓冲溶液，在振荡条件下加入异槲皮苷溶液反应，反应后经洗涤得到BSA@ISO；B、将RVG29多肽溶在PBS中，加入步骤A中BSA@ISO溶液，搅拌反应后，经透析、离心得到BSA@ISO‑RVG29；C、向Ti2C中加入1‑(3‑二甲氨基丙基)‑3‑乙基碳二亚胺盐酸盐，接着加入N‑羟基琥珀酰亚胺，反应后加入步骤B中的BSA@ISO‑RVG29反应，反应后经洗涤得到Ti2C‑BSA@ISO‑RVG29。在牛血清白蛋白包裹疏水药物异槲皮苷(ISO)，并接枝RVG29靶向肽，之后装载在具有强自由基清除能力的Ti2C纳米酶上，成功制备了用于缺血性卒中治疗的纳米制剂。
Resumen de: US2025186343A1
An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.
Resumen de: WO2025122024A1
The present invention discloses the use of local chemotherapy after laser hyperthermia treatment of a brain tumour. A pharmaceutical composition for local postoperative chemotherapy comprises a chemotherapy drug, in particular doxorubicin, loaded into nanoparticles obtained from a copolymer of amino acids that are natural metabolites in the brain.
Resumen de: WO2025121735A1
The present invention relates to a nano-platform comprising core-shell structured upconversion nanoparticles, a composition comprising same, and a treatment method, the nano-platform comprising: a core formed of NaYF4:Yb, Tm through single-step synthesis; and a shell, which encompasses the core and is formed of NaYF4:Nd.
Resumen de: WO2025122871A1
The present disclosure is directed, in some aspects, to oligonucleotide dendrimers comprising a molecular core covalently linked to one or more first oligonucleotide branches, wherein the molecular core is a polyethylene glycol (PEG) core, a polyester (PE) core, or a polyaminoamine (PAMAM) core. The disclosure also provides methods of making and/or using the oligonucleotide dendrimers for, e.g., treating a disease via inducing an immune response.
Resumen de: WO2025119217A1
Provided are a new cationic lipid compound, and a preparation method therefor, a composition thereof and the use thereof. The cationic lipid has a structure as represented by formula I. Lipid nanoparticles prepared from the cationic lipid have a stable nanostructure, have a relatively narrow size distribution, and can be stored for a relatively long time at a low temperature. Moreover, the lipid nanoparticles have relatively good biocompatibility and a relatively high in-vivo mRNA transfection efficiency. The core structures of the cationic lipids can all be constructed by means of a Ugi reaction. The reaction involves simple operation and mild reaction conditions, does not require additional catalysts, has high atomic economy, is simple and easy to carry out, and incorporates inexpensive and readily available raw materials, such that not only is higher safety provided, but the industrial production and quality control of the cationic lipids are also facilitated. The new cationic lipid has good application prospects.
Resumen de: WO2025118472A1
Provided is an anti-MET nanobody and an anti-EGFR nanobody, and a bispecific antibody comprising the two nanobodies. Also provided is a drug conjugate constructed on the basis of the nanobodies and the bispecific nanobody.
Resumen de: US2025186357A1
The present application relates to ionizable lipids that include ester functional groups. The present application further relates to compositions and uses thereof for the delivery of agents such as nucleic acids and drugs.
Resumen de: WO2025118118A1
Carbon monoxide core-shell nanoparticles capable of intravenous administration, a preparation method therefor, and use thereof, belonging to the technical field of nanomedicine. The preparation method for the carbon monoxide core-shell nanoparticles comprises: 1. preparing a polymer carrier PLGA(CO); 2. purifying the PLGA(CO); 3. weighing the PLGA(CO) and a functional material, dissolving them in THF, adding deionized water after ultrasonication, blowing off THF by using nitrogen, carrying out co-precipitation, centrifuging, washing, and carrying out co-precipitation to obtain a nanoparticle functional material @PLGA(CO); and 4. weighing DSPE-PEG, and reacting with the functional material @PLGA(CO) to obtain a functional material @PLGA(CO)@PEG. After a tail intravenous injection, the core-shell structure nanoparticles target a cancer site by means of intravenous injection under the monitoring of NIR-II fluorescence, and CO-enhanced mild temperature photothermal therapy is achieved to eliminate tumors.
Resumen de: AU2023375897A1
Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Resumen de: AU2025203628A1
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
Resumen de: US2025186431A1
Provided is a pharmaceutical composition for use in radiotherapy, comprising: a compound represented by formula (I) wherein R1 is an aryl group substituted with a substituent selected from an iodine atom and others, wherein the aryl group is optionally substituted with a substituent such as a hydroxy group, X represents a bond or the like and ring A is a group represented by formula (A), wherein R2 is a non-aromatic heterocyclic group optionally substituted with at least one C1-C4 alkyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. Also, provided is a nanoparticle and a method for treating solid cancer using the compound.
Resumen de: US2025188140A1
The present disclosure relates to a lipid-like nanoparticle encapsulating a C—C motif chemokine ligand 5 (CCL5) mRNA and methods of use thereof.
Resumen de: US2025188191A1
The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.
Nº publicación: US2025188132A1 12/06/2025
Solicitante:
MODERNATX INC [US]
ModernaTX, Inc
Resumen de: US2025188132A1
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
BOPI
Sede Electrónica
